Fiji Kava (ASX:FIJ) - MD & Founder, Zane Yoshida
MD & Founder, Zane Yoshida
Source: The Carousel
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Health and wellness company, Fiji Kava (FIJ) has put in precautionary measures and protocols due to the coronavirus (COVID-19)
  • The company has reduced the CEO’s remuneration and board fees by 20 per cent for the remainder of the 2020 financial year
  • Due to the Fiji Government placing restrictions on travel, the company has placed employees in its mobile processing units across Fiji
  • Coles has confirmed Fiji Kava’s ‘Noble Kava’ capsules will be ranged online and in all 812 stores, along with its new Noble Calm, Sleep and Beauty capsules
  • On market close, Fiji Kava is up 2.13 per cent and is trading for 4.8¢ per share

Health and wellness company, Fiji Kava (FIJ) has put in precautionary measures and protocols due to the coronavirus (COVID-19).

The company has reduced CEO Zane Yoshida’s remuneration and board fees by 20 per cent for the remainder of the 2020 financial year.

Due to the Fiji Government placing restrictions on travel, the company has placed employees in its mobile processing units across Fiji to minimise disruption to day to day operations.

Fiji Kava is still able to freight raw materials out of Fiji, despite the travel restrictions. The company is still supplying its products to Coles supermarkets.

Coles has confirmed Fiji Kava’s ‘Noble Kava’ capsules will be ranged online and in all 812 stores, along with its new Noble Calm, Sleep and Beauty capsules. At this time, the products are still expected to be on the shelf in Coles Supermarkets in June.

Employees are now working remotely when they can, the company is using technology to remain connected and continue ‘business as usual.’

Founder and CEO Zane Yoshida says Fiji Kava will continue to work hard to consolidate its business in the challenging global market.

“We are well placed to negotiate the uncertainty we are all faced with by COVID-19, following instituted safe working practises for all staff worldwide, our recent successful $2.3 million raising and our products classification as an essential
industry,” he said.

“Based on what we know today, we believe we are in a position to maintain our growth trajectory and supply increasing demand, as the world seeks anxiety relief in these stressful times,” he added.

On market close, Fiji Kava is up 2.13 per cent and is trading for 4.8¢ per share.

FIJ by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…